Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of August 1, 2025 • 10:31 PM ET

Date/Time Source News Release
07/29/2025 04:07 PM EDT GlobeNewswire Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
07/29/2025 04:05 PM EDT GlobeNewswire Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
06/17/2025 04:05 PM EDT GlobeNewswire Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
06/02/2025 04:05 PM EDT GlobeNewswire Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
05/08/2025 04:05 PM EDT GlobeNewswire Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
04/23/2025 04:05 PM EDT GlobeNewswire Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
04/15/2025 04:10 PM EDT GlobeNewswire Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/15/2025 04:05 PM EDT GlobeNewswire Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
03/08/2025 07:33 AM EST Canada Newswire Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
02/27/2025 04:05 PM EST GlobeNewswire Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Page